ENTERA BIO LTD. Restricted Cash
ENTERA BIO LTD. (ENTX) had Restricted Cash of $7.12 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCash · last filed 2026-08-07
- 2026-06-30: Restricted Cash $7.12M.
- 2026-03-31: Restricted Cash $7.79M.
- 2025-12-31: Restricted Cash $7.78M.
- 2025-09-30: Restricted Cash $8.03M.
| Period end | Restricted Cash |
|---|---|
| 2026-06-30 | $7.12M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $7.79M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $7.78M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $8.03M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $8.02M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $8.00M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |